Entera Bio Ltd
NASDAQ:ENTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Entera Bio Ltd
Cost of Revenue
Entera Bio Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cost of Revenue
-$42k
|
CAGR 3-Years
25%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cost of Revenue
-$104.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cost of Revenue
-$12.4m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
|
N
|
Neurosense Therapeutics Ltd
NASDAQ:NRSN
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cost of Revenue
-$795k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-22%
|
|
Entera Bio Ltd
Glance View
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. The firm conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The firm develops drugs for hypoparathyroidism, osteoporosis and bone healing.
See Also
What is Entera Bio Ltd's Cost of Revenue?
Cost of Revenue
-42k
USD
Based on the financial report for Dec 31, 2025, Entera Bio Ltd's Cost of Revenue amounts to -42k USD.
What is Entera Bio Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
33%
Over the last year, the Cost of Revenue growth was 76%. The average annual Cost of Revenue growth rates for Entera Bio Ltd have been 25% over the past three years , 33% over the past five years .
